Tag: myeloid-leukemia

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

| April 6, 2015 | 0 Comments

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

Continue Reading

MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia

| April 3, 2015 | 0 Comments

( University of Texas M. D. Anderson Cancer Center ) The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Continue Reading

MD Anderson, Astellas Pharma Sign Option Agreement

| April 3, 2015 | 0 Comments

The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Continue Reading

Leading Experts in the Field of AML Treatment and Bone Marrow Transplant to Discuss Available Treatment Options and …

| May 13, 2014 | 0 Comments

Actinium Pharmaceuticals, Inc.

Continue Reading

Mom, son fight cancer together, find 'new normal'

| December 17, 2013 | 0 Comments

For the Perry family, Christmas this year will be a little different.The festivities will not be held at grandma’s house, or at home in Nashua, N.H., but in a hospital room where Owen Perry, 12, is receiving treatment for acute myeloid leukemia.

Continue Reading

Systems medicine paves way for improved treatment for leukemia patients

| December 12, 2013 | 0 Comments

A new individualized systems medicine strategy enables a selection of potentially effective cancer therapies for individual patients. These are promising results achieved by applying this strategy to chemoresistant adult acute myeloid leukemia patients.

Continue Reading

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

| January 18, 2013 | 0 Comments

University of Rochester Medical Center scientists have proposed a new reason why acute myeloid leukemia, one of the most aggressive cancers, is so difficult to cure: a subset of cells that drive the disease appear to have a much slower metabolism than most other tumors cells.

Continue Reading

ARIAD and the U.K. National Cancer Research Institute to Collaborate on SPIRIT 3 Clinical Study

| January 7, 2013 | 0 Comments

ARIAD Pharmaceuticals, Inc. and Newcastle University, U.K., on behalf of the U.K.

Continue Reading

Local research study could lead to cure for acute myeloid leukemia

| December 26, 2012 | 0 Comments

The majority of people diagnosed with acute myeloid leukemia (AML) today cannot be cured, despite the aggressive therapies available. But a local researcher is working on a study that may help doctors learn more about the cells that cause leukemia so they can develop new treatments to destroy them.

Continue Reading